MF
FATE icon

Magnetar Financial’s Fate Therapeutics FATE Stock Holding History

Magnetar Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,831
Closed -$318K – 1408
2022
Q2 		$318K Buy
+12,831
New +$354K ﹤0.01% 1229
2021
Q3 		– Sell
-4,292
Closed -$373K – 1372
2021
Q2 		$373K Buy
+4,292
New +$346K ﹤0.01% 970

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Magnetar Financial's FATE Position: Q3 2022 in Review

Magnetar Financial sold out of Fate Therapeutics (FATE) in Q3 2022, closing a stake of 12,831 shares — an estimated $318K sold.

Magnetar Financial first reported a position in FATE in Q2 2021 and held it in 2 quarters. The position peaked at $373K in Q2 2021. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • Magnetar Financial reported no remaining Fate Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Magnetar Financial sold 12,831 Fate Therapeutics shares in Q3 2022, an estimated $318K.
  • Magnetar Financial first reported a position in Fate Therapeutics in Q2 2021 and held it in 2 quarters.
  • Magnetar Financial's Fate Therapeutics position peaked at $373K in Q2 2021.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Magnetar Financial's 13F filing for Q3 2022, filed 14 Nov 2022.